Beyond the Wound: Photobiomodulation as a Daily Metabolic Intervention in Type 2 Diabetes

The problem with how we think about PBM in diabetic patients

The prevailing clinical application of photobiomodulation in diabetic patients is local and reactive. A wound isn't healing — apply PBM to the wound. Neuropathic pain in the foot — treat the nerve distribution. Post-surgical recovery is stalled — add light to the surgical site. These applications have a reasonable evidence base and they work, to a degree.

But they misunderstand the patient. The diabetic patient with a non-healing wound or a neuropathic foot or a post-surgical complication does not have a local problem. They have a systemic metabolic environment that has compromised the local tissue. Treating only the site is addressing the symptom while leaving the environment intact.

Persistent hyperglycemia drives mitochondrial dysfunction through reactive oxygen species overproduction, endothelial impairment, advanced glycation end-product accumulation, and chronic inflammatory signaling that disrupts macrophage polarization and healing phase transitions. These processes are not limited to the wound or the nerve. They are pervasive — in the muscle, the gut epithelium, the liver, the adipose tissue, and the vascular endothelium that supplies every tissue you are trying to heal.

The clinical question is not: can PBM help this wound? The clinical question is: can PBM address the biological environment that is making this patient's tissue universally harder to heal?

Answering that question requires a different treatment model. Not local and reactive. Systemic and daily.

What the dose-response data tells us about frequency

The most informative trial for the dosing question is Scontri et al. (2023, J Biophotonics, PMID 37171054), a randomized crossover double-blind sham-controlled trial examining dose and time-response effects of PBM on glycemic control in T2DM patients.

The protocol applied 830 nm LED arrays bilaterally to eight skeletal muscle sites — quadriceps, hamstrings, triceps surae, and ventral upper arm and forearm — at three doses (0 J sham, 100 J, 240 J per site), with and without concurrent oral hypoglycemic medication. Capillary glycemia was measured at pre-prandial baseline, 1 hour postprandial (pre-PBM), and then at 30 minutes, 3 hours, 6 hours, and 12 hours post-PBM.

The results are worth reading carefully. Both 100 J and 240 J doses produced statistically significant reductions in glucose tolerance test AUC compared to sham. The 100 J dose reduced AUC by 37% without medication. Glycemic effects were detectable at 30 minutes and sustained to the 12-hour measurement window, with some evidence of attenuation between 6 and 12 hours.

If the acute metabolic effect of a single PBM session lasts approximately 6–12 hours and then attenuates, the biological rationale for daily application follows directly.

This is not established by any daily-dosing RCT. But the inference is not speculative — it is the same reasoning applied to any time-limited biological intervention. The question is not whether daily is better than weekly. The question is whether the mitochondrial and metabolic environment can be maintained in a persistently improved state through daily stimulation, rather than allowed to return to baseline between sessions.

We do not yet have long-term daily-dosing RCTs that answer whether cumulative benefit accrues with daily vs. every-other-day vs. 3x/week protocols. That is a genuine gap. What the Scontri data does establish is that the effect is real, the mechanism is mitochondrial, and the duration is bounded. Daily dosing is the logical next question, not a commercial assumption.

Skeletal muscle as the primary metabolic target

The multi-site delivery protocol in Scontri et al. deserves more attention than it has received. The choice to irradiate eight major bilateral muscle groups was not arbitrary — it reflects a fundamental truth about glucose metabolism that is often lost in the PBM wound-care literature.

Skeletal muscle accounts for approximately 70–80% of insulin-stimulated glucose disposal in healthy adults. In T2DM, impaired skeletal muscle glucose uptake — driven by mitochondrial dysfunction, reduced GLUT4 translocation, and impaired insulin signaling cascade — is the primary mechanism of postprandial hyperglycemia. This is not peripheral to the disease. It is the disease, metabolically.

Gong et al. (Aging, 2021) demonstrated that PBM therapy ameliorates hyperglycemia and insulin resistance specifically through cytochrome c oxidase-mediated activation of protein kinase B (Akt) in skeletal muscle — the same kinase that mediates insulin receptor substrate signaling and GLUT4 translocation to the cell membrane. The mitochondrial pathway and the insulin signaling pathway are not independent. They converge at the muscle cell.

The practical implication is significant. A diabetic patient treated with PBM for a foot wound using a local probe is receiving a categorically different intervention than a diabetic patient treated with PBM across bilateral lower extremities, core, and upper extremities for systemic metabolic effect. Both might be called PBM. They are not the same treatment.

The former treats a site. The latter treats a system.

The gut–liver–microbiome axis: an emerging third target

The most scientifically novel component of this framework is also the least clinically established. The evidence for PBM effects on the gut–liver–microbiome axis is real, compelling, and almost entirely preclinical. We present it as a mechanistically grounded hypothesis with preliminary biological support — not as an established intervention.

Min et al. (Cells, 2022, PMID 36359885) investigated duodenal dual-wavelength PBM (630/850 nm LED) in Goto-Kakizaki rats — a validated T2DM animal model. A single duodenal illumination session produced improvements in oral glucose tolerance test AUC, reductions in hepatic collagen deposition, and normalization of liver enzymes (AST, ALT, ALP), with effects comparable to radiofrequency ablation of the duodenal mucosa.

External transabdominal delivery cannot replicate intraluminal duodenal illumination in terms of fluence to the target tissue. Red light (630–660 nm) penetrates superficial tissue to 5–10 mm. Near-infrared (800–850 nm) penetrates significantly deeper — estimates suggest up to 40–60 mm in soft tissue under optimal conditions. Whether this is sufficient to produce biologically meaningful photobiomodulation at the intestinal wall and liver surface through the abdominal wall in humans is not established.

Separate from the hepatic and intestinal tissue effects, PBM has been shown to alter gut microbiome composition. Liebert et al. demonstrated significant differences in microbial diversity between mice receiving abdominal red/NIR irradiation and sham controls over a two-week period. The mechanism is hypothesized to involve PBM-induced reductions in intestinal oxidative stress and pro-inflammatory cytokines, which alter the intestinal environment in favor of beneficial microbial populations.

We are not claiming that transabdominal PBM reverses gut dysbiosis in diabetic patients. We are claiming that the mechanism by which it might do so is biologically coherent, that preliminary animal data supports the direction of effect, and that this is among the most important unanswered questions in PBM metabolic research.

Unanswered questions and research priorities

Intellectual honesty about the gaps is part of what makes the framework credible.

Does daily PBM produce cumulative metabolic benefit beyond single-session effects? No daily-dosing RCT in T2DM exists. The Scontri time-response data implies the question; it does not answer it. This is the highest-priority clinical trial that needs to happen.

What is the minimum effective dose for systemic metabolic effect? The 100 J vs. 240 J comparison in Scontri et al. showed comparable effects at the two doses tested. The lower boundary has not been established. This matters enormously for home-use device design and patient adherence.

Does transabdominal PBM reach the duodenal wall and liver with sufficient fluence in humans? Animal models support the biological effect. Human tissue penetration depth at relevant wavelengths through the full abdominal wall remains incompletely characterized.

Do PBM-induced microbiome shifts persist, and do they produce clinically meaningful metabolic changes? The animal microbiome data shows direction of effect. Duration, clinical significance, and specific taxa most responsive to PBM are not established in humans.

Conclusions

The diabetic patient does not have a local problem that a systemic disease has produced. They have a systemic metabolic impairment that manifests locally wherever healing is required. The current model of applying PBM to whatever hurts, one site at a time, is a mismatch between the intervention's biological potential and the disease's biological reality.

The literature, read as a whole rather than study by study, supports a different model: daily, multi-site, metabolically-targeted PBM that treats skeletal muscle as the primary insulin-sensitive tissue, incorporates transabdominal delivery toward the gut–liver axis, and is applied consistently enough to maintain the mitochondrial environment in a state of improved function rather than allowing repeated baseline deterioration.

This is not an established protocol. The RCTs that would confirm or refine it have not been done. What exists is a mechanistically coherent framework, a preliminary evidence base that points in a consistent direction, and a patient population for whom better tools are urgently needed.

This paper is a framework for clinical reasoning, not a treatment guideline. Education, not medical advice.

Rahul N. Desai MD is Chief Science Officer and Co-Founder of Redvive Health, which develops photobiomodulation devices. This paper represents independent scientific analysis; Redvive Health did not fund or commission this work. Readers should weigh this relationship in evaluating the conclusions.

Key References

1. Scontri CMCB et al. Dose and time-response effect of photobiomodulation therapy on glycemic control in type 2 diabetic patients. J Biophotonics. 2023;16(10):e202300083. PMID 37171054.

2. Min SH et al. Duodenal Dual-Wavelength Photobiomodulation Improves Hyperglycemia and Hepatic Parameters with Alteration of Gut Microbiome in Type 2 Diabetes Animal Model. Cells. 2022;11(21):3490. PMID 36359885.

3. Perrier Q, Moro C, Lablanche S. Diabetes in spotlight: current knowledge and perspectives of photobiomodulation utilization. Front Endocrinol. 2024;15:1303638. PMID 38567306.

4. Jiménez-García AM et al. Transabdominal photobiomodulation applications: A systematic review and meta-analysis. Obes Rev. 2025;26(8):e13921. PMID 40186373.

5. Gong L et al. Photobiomodulation therapy ameliorates hyperglycemia and insulin resistance by activating cytochrome c oxidase-mediated protein kinase B in muscle. Aging (Albany NY). 2021;13(7):10015-10033. PMID 33795530.

6. Wang K et al. Photobiomodulation for diabetes and its complications: a review of general presentation, mechanisms and efficacy. Ann Med. 2024;56(1):2433684. PMID 39607829.

7. Liebert A, Bicknell B et al. Photobiomodulation of the microbiome: implications for metabolic and inflammatory diseases. Photomed Laser Surg. 2019. PMID 30074108.